IO BIOTECH INC (IOBT)
US4497781090 - Common Stock
IO BIOTECH INC
NASDAQ:IOBT (1/14/2025, 8:00:02 PM)
After market: 0.81 -0.02 (-2.29%)0.829
-0.03 (-3.93%)
Company Profile
IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The firm develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The firm is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
Company Info
IO BIOTECH INC
Ole Maaloes Veh 3
COPENHAGEN
P: 4570702980
Employees: 68
Website: https://www.iobiotech.com/
IOBT News
6 days ago - IO BiotechIO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer-- Enrollment Completed Ahead of Schedule -- -- Initial Data Expected in 2025 -- NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq:...
26 days ago - IO BiotechIO Biotech secures up to €57.5 million in debt financing from the European Investment BankFunds expected to be used to advance IO Biotech’s immune-modulating therapeutic cancer vaccines, including potential BLA submission for IO102-IO103 in...
2 months ago - IO BiotechIO Biotech Reports Third Quarter 2024 Financial Results and Provides Business HighlightsIO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights...
2 months ago - IO BiotechIO Biotech Announces Participation in Upcoming Investor ConferencesIO Biotech Announces Participation in Upcoming Investor Conferences...
2 months ago - IO BiotechIO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study-- Metastatic non-small cell lung cancer (NSCLC) patients treated in the first line setting with IO102-IO103 in combination with Keytruda® demonstrated...
3 months ago - IO BiotechIO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingNEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf,...
IOBT Twits
Here you can normally see the latest stock twits on IOBT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
